Biotech Profile
Priothera – From Novartis Shelved Asset to Phase 3 in Five Years
Irish biotech Priothera is advancing mocravimod, a non-immunosuppressive S1P receptor modulator that the founding team rescued from Novartis’ pipeline, now targeting improved survival outcomes for AML patients undergoing stem cell transplantation. Co-founder Dr. Simone Seiter outlines how strategic protocol amendments
4 August 2025
